ArticleCirculation journal : official journal of the Japanese Circulation Society2019
A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Article in Circulation journal : official journal of the Japanese Circulation Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Clinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatment.Circulation reports · 2026Article
- Four Key Challenges After a Decade of Consecutive Paradigm Shifts in Wild-Type Transthyretin Amyloid Cardiomyopathy: From Rarely Found to Never Missed.Circulation reports · 2026Review
- Patient Characteristics and Diagnosis of Transthyretin Amyloid Cardiomyopathy in Japan: Baseline Analysis of J-COSSA.JACC. Asia · 2026Article
- Geographical Disparities in the Detection and Certification of Systemic Amyloidosis in Japan: A Nationwide Registry Analysis, 2015-2024.Circulation reports · 2026Article
- Better Outcomes After Initiation of Disease-Modifying Therapy in Patients with Transthyretin Cardiac Amyloidosis.Journal of clinical medicine · 2026Article
- One-year worsening heart failure and myocardial T1 mapping in patients with wild-type transthyretin amyloid cardiomyopathy undergoing tafamidis treatment.International journal of cardiology. Heart & vasculature · 2026Article
- Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid Cardiomyopathy.Circulation reports · 2026Article
- Technetium-99m-labeled pyrophosphate uptake in the rectum of a patient with wild-type transthyretin cardiac amyloidosis.Radiology case reports · 2026Article
- Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis.Annals of medicine · 2025Review
- Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation.European heart journal · 2025Article
- Feasibility and Safety of Atrial Biopsy - Evidence From 1,000 Cases.Circulation reports · 2025Article
- Real-World Clinical Impact of Tafamidis on Transthyretin Amyloid Cardiomyopathy - A Decade of Experience From a Community-Based Hospital (2015-2024).Circulation reports · 2025Article
- Myocardial T1 Mapping, Left Ventricular Parameters, and Cardiac Biomarkers in Wild-Type Transthyretin Amyloid Cardiomyopathy Before and After Tafamidis Treatment.Circulation reports · 2025Article
- Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration.The international journal of cardiovascular imaging · 2025Article
- Advancements in Cardiac Amyloidosis Treatment.Biomedicines · 2024Review
- Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy.ESC heart failure · 2023Observational
- Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis.Journal of clinical medicine · 2023Article
- Prevalence and Treatment of Arrhythmias in Patients With Transthyretin and Light-Chain Cardiac Amyloidosis.Circulation reports · 2023Article
- Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy.Pharmaceutics · 2023Review
- Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transthyretin cardiac amyloidosis is a progressive and life-threating disease that is significantly underdiagnosed, and the actual number of patients with the disease is presently unknown. Accumulation of wild-type transthyretin-derived amyloid in the heart is a common finding in very elderly patients. Recent clinical trials demonstrated that tafamidis reduced all-cause death and the number of cardiovascular hospitalizations when compared with placebo. The Japanese Ministry of Health, Labour and Welfare approved tafamidis (Vyndaqel
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.